ГоловнаArchive of numbers2016Volume 24, issue 3 (88)Ischemic stroke severity and cumulative proportion surviving in the patients with extracranial arteries atherosclerosis according to the severity of systemic infl ammation, previous and chronic infections, stroke-induced immunodepression
Title of the article Ischemic stroke severity and cumulative proportion surviving in the patients with extracranial arteries atherosclerosis according to the severity of systemic infl ammation, previous and chronic infections, stroke-induced immunodepression
Authors Sidorovich Emiliya
Amvrosieva Tamara
Likchachev Sergey
Goncharova Natalia
In the section DIAGNOSTICS AND THERAPY OF NEUROLOGICAL DISORDERS
Year 2016 Issue Volume 24, issue 3 (88) Pages 28-33
Type of article Scientific article Index UDK 616.831-005.6:613.13-004.6 Index BBK -
Abstract Based on the analysis of medical history, laboratory studies data in 308 ischemic stroke (IS) patients with extracranial arteries atherosclerosis systemic infl ammation, previous and chronic infections, stroke-induced immunosuppression severity variability was established. We applied IS phenotyping VIDA (Vospalenie, Infekcii, immunoDepressia, Antitela k virusu prostogo herpesa) with gradation of infl ammation, infections, immunodepression, and serum herpes simplex virus immunoglobulin M (IgM) antibodies detection. The total score VIDA 7 and more was associated with more pronounced neurological and functional defi cits, as well as with a reduction in cumulative proportion surviving at 3 year of observation to 45.5 % compared to 88.0 % at VIDA 6 and less (P < 0.05). The lowest survival rate was observed in the patients with diff erent combinations of VIDA components of highest grades: "V3, 4I2, 3D2А1, 0" (P < 0.05). VIDA phenotyping may be of practical importance to improve the strategies of anti-inflammatory and immunomodulatory IS patients treatment.
Key words Ischemic stroke phenotyping, systemic inflammation, infection, immunodepression, immunoglobulin M antibodies to herpes simplex virus, cumulative proportion surviving
Access to full text version of the article pdf download
Bibliography 1. Результаты применения комбинации ингибитора ГМГ- КОА-редуктазы и инозина пранобекса в комплексном лечении пациентов с инфарктом мозга при атеросклерозе экстракрани- альных артерий: влияние на уровень С-реактивного белка и по- казатели Т- и В-клеточного иммунного ответа / Э. К. Сидорович, Н. В. Гончарова, Л. Н. Гавриленко и др. // Лечебное дело. — 2015. — Вып. 6, № 46. — С. 27—36. 2. Statins and the Risk of Herpes Zoster: A Population-Based Cohort Study / Antoniou T., Zheng H., Singh S. et al. // Clinical Infectious Diseases. — 2014. — Vol. 58. — № 3. — P. 350—356. 3. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management / A. M. Arvin, J. S. Wolinsky, L. Kappos et al. // JAMA Neurol. — 2015. — Vol. 72. — № 1. — P. 31—39. 4. Early Statin Use is Associated with Increased Risk of Infection after Stroke / K. Becker, P. Tanzi, A. Kalil et al. // J Stroke Cerebrovasc Dis. — 2013. — Vol. 22. — № 1. — P. 66—71. 5. Chamorro A. Infection after acute ischemic stroke: a manifestation of brain-induced immunodepression / A. Chamorro, X. Urra, A. M. Planas // Stroke —2007. — Vol. 38. — № 3. — P. 1097—1103. 6. The immunology of acute stroke / A. Chamorro, A. Meisel, A. M. Planas et al. // Nat Rev Neurol. — 2012. — Vol. 8. —P. 401—410. 7. Di Napoli M. C-reactive protein in ischemic stroke: an independent prognostic factor./ M. Di Napoli, F. Papa, V. Bocola // Stroke. — 2001. — Vol. 32. — P. 917—924. 8. Herpesvirus Infections and Childhood Arterial Ischemic Stroke. Results of the VIPS Study / M. Elkind; N. Hills, C. Glaser et al. // Circulation. — 2016. — Vol. 133. — P. 732—741. 9. Enlimomab Acute Stroke Trial Investigators. Use of anti- ICAM- 1 therapy in ischemic stroke: results of the enlimomab acute stroke trial // Neurology. — 2001. — Vol. 57. — P. 1428—1434. 10. Emsley H. C. Acute ischaemic stroke and infection: recent and emerging concepts / H. C. Emsley, S. J. Hopkins // Lancet Neurol. — 2008. — Vol. 7. — P. 341—353. 11. Fitzgerald S. Third PML Case Associated with Fingolimod: How to Distinguish PML from MS Relapse / S. Fitzgerald // Neurology today. — 2015. — Vol. 8. — P. 10—11. 12. Impact of an immune modulator fingolimod on acute ischemic stroke / Y. Fu, N. Zhang, L. Ren et al. // Proc Natl Acad Sci USA. — 2014. — Vol. 111. — P. 18315—18320. 13. Gauberti M. The “inflammatory penumbra” in ischemic stroke: From clinical data to experimental evidence / M. Gauberti, S. M. De Lizarrondo, D. Vivien // European Stroke Journal. — 2016. — Vol. 1. — № 1. — P. 20—27. 14. Grimaldi D. Post-infectious immune suppression: a new paradigm of severe infections/ D. Grimaldi, J. F. Llitjos, F. Pène // Med Mal Infect. — 2014. — Vol. 44. — № 10. — P. 455—463. 15. Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke/ A. Liesz, W. Zhou, E. Mracsko et al. // Brain. — 2011. — Vol. 134. — P. 704—720. 16. Lindsberg P. J. Inflammation and infection as risk factors for ischemic stroke / P. J. Lindsberg, A. J. Grau // Stroke. — 2003. — Vol. 34. — P. 2518—2532. 17. Results of a preclinical randomized controlled multicenter trial (pRCT): anti-CD49d treatment for acute brain ischemia / G. Llovera, K. Hofmann, S. Roth et al. // Sci Transl Med. — 2015. — Vol. 7. — № 299. — P. 299ra121. 18. Acute ischemic stroke: time, penumbra, and reperfusion / N. W. Manning, B. C. Campbell, T. J. Oxley et al. // Stroke. — 2014. — Vol. 45. — P. 640—644. 19. Inflammatory and Neurodegeneration Markers during Asymptomatic HSV-1 Reactivation / C. Martin, B. Aguila, P. Araya et al. // Journal of Alzheimer’s Disease. — 2014. — Vol. 39. — № 14. — P. 849—859. 20. Perry V. H. Systemic infections and inflammation affect chronic neurodegeneration / V. H. Perry, C. Cunningham, C. Holmes // Nat Rev Immunol. — 2007. — Vol. 7. — P. 161—167.